IAPTURECO PLIPIT 7.2. IF L. 7001										
	PTO-1 01-200		E PATENT & TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 126068						
		ANSMITTAL LETTER TO T ESIGNATED/ELECTED OF	U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/557,922							
		ONCERNING A FILING UN	13333,1022							
	RNAT	TIONAL APPLICATION NO. 003/006422	PRIORITY DATE CLAIMED							
PCT/JP2003/006422 May 22, 2003  TITLE OF INVENTION COMPOUNDS AND PREPARATIONS HAVING ANTIVIRAL EFFECT										
APPLICANTS FOR DO/EO/US										
Masao MORI; Haruo SAITO; Hideo NEMOTO; Naoki YAMAMOTO; Masao HATTORI  Applicant berevith submits to the United States Designated/Florted Office (DO/FO/US) the following items and other information:										
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:  1.										
1.	=	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.								
2.	⊠ ⊠	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.								
3.	M	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.								
4.		The US has been elected (Article 31).								
5.		A copy of the International Application as filed (35 U.S.C. 371(c)(2))								
l		a.  is attached hereto (required only if not communicated by the International Bureau).								
		b.  has been communicated by the International Bureau.								
		c. $\square$ is not required, as the application was filed in the United States Receiving Office (RO/US).								
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))								
		a. 🔲 is attached hereto.								
		b.  has been previously submitted under 35 U.S.C. 154(d)(4).								
		c.	n was filed in English.							
7.		Amendments to the claims of the Ir	nternational Application under PCT	Article 19 (35 U.S.C. 371(c)(3))						
		a.   are attached hereto (required only if not communicated by the International Bureau).								
		b.  have been communicated by the International Bureau.								
		c.  have not been made; however, the time limit for making such amendments has NOT expired.								
		d.  have not been made and will not be made.								
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).								
9.	$\boxtimes$	An oath or declaration of the inventors (35 U.S.C. 371(c)(4)).								
10.		An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).								
Item	s 11 t	o 20 below concern document(s)	or information included:							
11.		An Information Disclosure Stateme	ent under 37 CFR 1.97 and 1.98.							
12.		An assignment document for record	ding. A separate cover sheet in co	mpliance with 37 CFR 3.28 and 3.31 is included.						
13.		A preliminary amendment.								
14.		An Application Data Sheet under 37 CFR 1.76.								
15.		A substitute specification.								
16.	⊠	A power of attorney and/or change	of address letter.							
17.		A computer-readable form of the sequence listing in accordance with PCT Rule 13 <i>ter</i> .2 and 37 CFR 1.821 - 1.825.								
18.		A second copy of the published international application under 35 U.S.C. 154(d)(4).								
19.		A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).								
20.	⊠	Other items or information: Transmittal of Power of Attorney and Statement								
20. 20. Control of morning of the original of										

U.S. APPLICATION NO. (if known 10/5,57,922	n, see 37 C.F.R. 1.5)	ATTORNEY'S DOCKET NUMBER								
21.   The following fee	0/5,57,922 PCT/JP2003/006422 1. ☑ The following fees are submitted:				CALCULATIONS PTO USE ONLY					
-										
BASIC NATIONAL FEE (3			\$ 300.00	\$						
SEARCH FEE (37 CFR 1.	492(b)(1)-(3)):	\$								
International preliminary extended the USPTO as IPEA or IS industrial applicability for a national stage	A and favorable as to ill claims presented in									
International search fee (3	7 CFR 1.445(a)(2)) p									
International search report the search fee is paid	provided to USPTO									
All situations not provided	for above									
EXAMINATION FEE (37 C		\$								
International preliminary examination report or written opinion prepared by the USPTO as IPEA or ISA and favorable as to novelty, inventive step, and industrial applicability for all claims presented in the application entering the national stage										
Surcharge of \$130.00 for for earliest claimed priority da	urnishing the oath or	declaration later than 3	0 months from the	\$130.00						
TOTAL PAGES OF APPLICATION OVER 100 ( - 100)	÷ 50	= †	x 250 =	\$						
fround up to next integer	er	1								
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$						
TOTAL CLAIMS	- 20	=	x 50.00 =	\$						
INDEPENDENT CLAIMS	- 3	=	x 200.00 =	\$						
MULTIPLE DEPENDENT		e) TOTAL OF ABOVE (	+ 360.00 =	\$						
Applicant claims arrell		\$130.00								
Applicant claims small reduced by ½.	entity status. See 3	indicated above are	\$							
		\$130.00								
Processing fee of \$130.00 the earliest claimed priority	for furnishing the Eng date (37 CFR 1.492)	glish translation later th (f)).	an 30 months from	\$						
		\$130.00								
Fee for recording the enclo accompanied by an approp	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +									
		TOTAL FE	ES ENCLOSED =	\$130.00						
	0 10557922	Amount to be refunded:	\$							
FC:1617	130,00 00	4400.00		charged:	\$					
<ul> <li>a.</li></ul>										
c. 🛛 The Commission Deposit Accour										
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.										
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.										
SEND ALL CORRESPON		·	- (	/						
OLIFF & BERRIDGE, PLC  Customer Number: 25944  NAME: James & Oliff										
Customer Numbe	I. 20944		NAME: Jame REGISTRATIO	s/A. Oliff VN NUMBER: 27,0	75					
Date <u>December 22, 2</u> 0	Date <u>December 22, 2005</u> NAME: Jesse O. Collier  REGISTRATION NUMBER: 53,839									
			V							

## **PATENT APPLICATION**

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Masao MORI et al.

Application No.: 10/557,922

Filed: November 22, 2005

Docket No.: 126068

For:

COMPOUNDS AND PREPARATIONS HAVING ANTIVIRAL EFFECT

## TRANSMITTAL OF POWER OF ATTORNEY AND STATEMENT UNDER 37 CFR § 3.73(b)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith is a Power of Attorney from the Assignee.

In compliance with 37 CFR §3.73(b), the undersigned hereby states that LEAD CHEMICAL CO., LTD. is the assignee of the entire right, title and interest in the patent application identified above by virtue of an assignment from the inventors of the patent application identified above. A copy of the assignment is attached hereto and is concurrently being submitted for recordation.

The undersigned is authorized to act on behalf of the assignee.

In accordance with 37 CFR §1.36(a), submission of this Power of Attorney revokes any powers of attorney previously given.

ALL CORRESPONDENCE IN CONNECTION WITH THIS APPLICATION SHOULD BE SENT TO OLIFF & BERRIDGE, PLC, CUSTOMER NO. 25944, TELEPHONE (703) 836-6400.

Respectfully submitted,

Registration No. 36,430

JSA/mps

Date: December 22, 2005